sur TRANSGENE (EPA:TNG)
Transgene presents its progress and financial situation as of Q3 2025
Transgene has shared promising new data regarding its TG4050 therapeutic vaccine, which focuses on preventing relapses of head and neck cancer. Presented at the SITC 2025 congress, this data reinforces the vaccine's potential as a monotherapy to generate effective immune responses.
The company also highlighted the progress of its myvac® platform for treating various types of operable solid tumors. In parallel, promising results from the BT-001 study, an oncolytic virus, were unveiled at ESMO 2025, demonstrating good antitumor activity in combination with anti-PD-1 therapy.
On the financial front, Transgene noted an increase in its Research Tax Credit, reaching €5.8 million in Q3 2025. With cash of €12.8 million as of September 30, 2025, the company remains funded until the end of 2026, thanks to significant support from its main shareholder.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE